Tasly Pharmaceutical (SHA:600535) obtained a drug registration certificate for Wenjing Decoction Granules, according to a Shanghai bourse disclosure on Tuesday.
The drug is used to treat patients with irregular menstruation, abdominal pain, and deep, tight pulse.
The Chinese pharmaceutical company invested 10.7 million yuan into the research and development of the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments